Irene Soulsby

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Top Venues

BMJ (Clinical research ed.)

Sociology of health & illness

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Liz Forbat, Aisha Macgregor, Talitha Brown, Brendan George McCormack, Karen Spilsbury, Alasdair C Rutherford, Barbara Hanratty, Jo Hockley, Maisie McKenzie, Irene Soulsby, Margaret Ogden
Negotiating pace, focus and identities: Patient/public involvement/engagement in a palliative care study. Sociology of health & illness (2024)
Miriam Santer, Megan Lawrence, Sarah Pyne, Susanne Renz, Beth L Stuart, Tracey H Sach, Matthew J Ridd, Kim Suzanne Thomas, Jacqueline Nuttall, Natalia Permyakova, Zina Eminton, Nick A Francis, Paul Little, Ingrid Muller, Irene Soulsby, Karen Thomas, Gareth O Griffiths, Alison Margaret Layton
Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT. Health technology assessment (Winchester, England) 28 (56) (2024)
Miriam Santer, Megan Lawrence, Susanne Renz, Zina Eminton, Beth L Stuart, Tracey H Sach, Sarah Pyne, Matthew J Ridd, Nick A Francis, Irene Soulsby, Karen Thomas, Natalia Permyakova, Paul Little, Ingrid Muller, Jacqueline Nuttall, Gareth O Griffiths, Kim Suzanne Thomas, Alison Margaret Layton, null null
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ (Clinical research ed.) 381 (2023)
Miriam Santer, Megan Lawrence, Susanne Renz, Zina Eminton, Beth L Stuart, Tracey H Sach, Sarah Pyne, Matthew J Ridd, Nick A Francis, Irene Soulsby, Karen Thomas, Natalia Permyakova, Paul Little, Ingrid Muller, Jacqueline Nuttall, Gareth O Griffiths, Kim Suzanne Thomas, Alison Margaret Layton, null null
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ (Clinical research ed.) 381 (2023)